Skip to main content
Message Font: Serif | Sans-Serif
 
No. of Recommendations: 0
Interesting.

HIV patients have abnormal fat distribution at baseline, resulting in accelerated coronary disease as well. I'd be curious if they could do a large (couple thousand) patient study of egrifta vs placebo and demonstrate a decrease in ACS or mortality. THAT'S the money shot. Also, its incredibly costly to run that sort of trial.

Sadly, egrifta has been around for 8+ years and still <100m sales and theratech either hasnt thought of doing such a trial, or it wouldnt work. The NASH play is certainly intriguing, but it's not for me; I have to trust a management team to push and show a vision for me to invest. Not saying THERF may not be a profitabl trade, but its not for me.
Print the post  

Announcements

What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.